In this connection, security issues ...

In this regard, the security of antiepileptic therapy is one of the main objectives of this study, which attempted to use in adolescents with epilepsy Lamiktala known as the drug is not only a wide range of actions, but also having a positive influence on cognitive function and affective [3,4,5,8,10,11,12,13,17,18,19,20]. Lamiktal in epilepsy treatment is used in Russia for more than 10 years. Experience in our clinic (about 7 years) allows us to generalize the results of therapy in patients of different age groups (250 patients), which makes it possible to consider separately the juvenile epilepsy. It should be pointed out that due to numerous safety studies Lamiktala and prevent the most dangerous of its side effects - Stevens-Johnson syndrome and toxic epidermoid necrosis due to the developed technique of titration Lamiktala, as well as more stringent criteria for patient selection, with the exception of those with a history or allergological signs of liver failure - is now a danger of complications decreased dramatically, and not only when monotherapy these drugs, but also in terms of its combination with other anticonvulsants, in some cases dictated by clinical indications. Currently, it has been established that the decline in capacity of initial doses Lamiktala, subject to subsequent treatment titration resulted in a reduction to 10 times the number of toxic side effects (B. Boourgeois, at al. 2002). Monotherapy Lamiktalom held 10 teenagers in two versions: as of an initial (5 patients who have not received any anticonvulsants) and the so-called secondary monotherapy (5 patients with previously ineffective therapy other anticonvulsants), with their complete replacement Lamiktalom and subsequent monotherapy these drugs. As adjunctive therapy Lamiktal was applied in 1924 for adolescents and youths. Methods of treatment included along with a strict selection of patients in the study, monitoring of somato-neurological and mental functions, as well as assessment of the dynamics in the therapy of these neuropsychological examination, and some personality tests. All participants underwent an EEG study of at least 1 time in 3 months, and biochemical blood tests. In accordance with generally accepted standards, titrated doses of an initial Lamiktala with monotherapy was conducted in steps, with increased daily dose 12.5 mg every 5 days to achieve partial or complete seizure control at the optimal dose of the drug, with an average of 100-200 mg / day in 2 admission. Depending on the rate of titration of the drug were changed (no dose adjustment). The tactics of an initial adjunctive therapy of these drugs with subsequent transfer to the secondary monotherapy Lamiktalom included, as in the primary alone, 2-week buildup Lamiktala, with the persistent dose of another anticonvulsant, and then held back titrated doses of both drugs.